

CASE REPORT

Solitary Fibrous Tumor of the Masticator Space with Unusual Extension: a Case Report

Evangelos GIOTAKIS^a, Athina ZARACHI^b, Spyridoula DERKA^c, Georgios PAVLIDIS^d, Aikaterini LIANOUB^b, Victoria TSOUMANI^b, Angelos LIONTOS^e, Evangelos TSIAMBAS^f, Vasileios RAGOS^g

^a1st ENT University Clinic, National and Kapodistrian University of Athens, Greece

^bDepartment of Otorhinolaryngology, Head and Neck Surgery, School of Health Sciences, University Hospital of Ioannina, University of Ioannina, Ioannina, Greece

^cMaxillofacial Surgeon, Attikon Hospital, Greece

^dEndovascular Neurosurgeon, Director of International Neuroradiology department, Euroclinic Hospital, Athens, Greece

^eDepartment of Pathology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece

^fDepartment of Cytology, 417 Army Veterans' Hospital, Athens, Greece

^gDepartment of Maxillofacial Surgery, Medical School, University of Ioannina, Ioannina, Greece

ABSTRACT

Background: We present the case of a patient with solitary fibrous tumor of the masticator space with unusual extension.

Case presentation: A 43-year-old woman presented with a painless mass with intraoral extension on the right cheek. The B-scan sonograph and magnetic resonance imaging revealed the extension of the tumor. The biopsy performed under local anesthesia raised the suspicion of a solitary fibrous tumor. Tumor excision included a preoperative tumor embolization. The surgical removal of the tumor included a partial parotidectomy on the right side, insertion of masseteric and temporalis muscle, resection of the middle part of the zygomatic bone and stabilization of the bone with a plate, mobilization of the tumor from the maxillary sinus and the pterygopalatine fossa through an endoscopic approach and an approach via partial resection of the anterior wall of the maxillary sinus after identifying and sparing the infraorbital nerve. The histological findings confirmed the diagnosis of solitary fibrous tumor. The patient's treatment completed with radiation therapy, and 2.5 years later, there was recurrence in the right temporal area.

Address for correspondence:

Athina Zarachi

Mailing address: Stavroy Niarchoy Avenue, Ioannina, Greece

Tel: +306979007589; email: athinazarachi@gmail.com

Article received on the 4th of December 2023 and accepted for publication on the 23rd of February 2024

Conclusions: To our knowledge, this is the second reported case of solitary fibrous tumor arising in the masticator space and the only case with extension intraorally and in the paranasal sinuses. Tumor embolization and complete surgical excision are the most frequently recommended treatments.

Keywords: solitary fibrous tumor, masticator space, mesenchymal tumor.

INTRODUCTION

Solitary fibrous tumor (SFT) is a rare mesenchymal tissue neoplasm that occurs at all anatomic sites, commonly at the pleura. It is estimated that less than 2% of all soft tissue masses are solitary fibrous tumors (SFTs). The extra thoracic detection is rare and the incidence in the head and neck region is exceedingly rare (1-16).

The first detailed histological description of SFTs was reported by Wagner in 1870 (17). Later in 1931, Klemperer and Rabin described SFTs in pleural tumors (18). Although various opinions have been expressed about SFTs and hemangiopericytomas, both tumors are considered separate entities, according to 2002 WHO classification (19).

It is estimated that 25% of extra pleural SFT and 6-18% of all SFTs arise from the head and neck region (20-22). Within this anatomic region, it usually offends the orbit and the oral cavity. Less frequently, it affects the nasal cavity and paranasal sinuses, the salivary gland and larynx (23). Nevertheless, only few cases have been reported to SFT departing from the buccal mucosa (24-27).

These tumors grow slowly, show minimal malignant variants, while metastases appear in tumors outside the head and neck area (28, 29).

The STAT6 nuclear protein and the NAB2-STAT6 fusion gene appear to play an important role in immunohistochemistry and molecular diagnosis. The 2020 WHO classification recommended risk models to determine the prognosis of SFT more clearly (6, 14, 30-32).

We report the case of a solitary fibrous tumor of the buccal space which presents an unusual extension to adjacent tissues. □

CASE PRESENTATION

In July 202, a 43-year-old woman presented with inability to open the mouth and abnormal right lateral jaw dislocation for about two months.

As the patient had difficulty in eating properly, she previously referred to a local dental infirmary in the Greek island where she lives. Following the dentist's medical instructions, she received muscle relaxant therapy without permanent effect.

During clinical examination, a well-circumscribed, smooth and painless tumor mass was palpated on the right cheek. The mass had intraoral extension (Figure 1). The patient also presented trismus and lateral right displacement of the lower jaw. On B-scan sonography we detected a well-circumscribed inhomogeneous tumor with high peripheral vascularity and a maximum diameter of 3 cm. Magnetic resonance imaging (MRI) revealed a solid mass into the right masticator space, showing mild high intense signal on T2 sequences and intermediate intense signal on T1 sequences. The mass with a maximum diameter of 4.1 cm was coming out of the right temporalis muscle, causing erosion of the posterior wall of the right maxillary sinus. Under local anesthesia, four pieces of tissue were obtained from the lesion and adjacent structures. The histological analysis raised the suspicion of a cell neoplasm compatible with SFT.

In February 2021, the patient decided to be treated for tumor exclusion. The MRI, which was performed for the evaluation of tumor resectabi-



FIGURE 1. Intraoral extension of the tumor




FIGURE 2. Magnetic resonance performed for the evaluation of the resectability of the tumor, showing a vascular mass with maximal diameter 5.7 cm that pushes the posterior wall of the right maxillary sinus and extends to the orbital floor




FIGURE 3. Right external carotid artery angiography, pre-embolization and post embolization

lity, revealed a vascular mass with a maximum diameter of 5.7 cm that pushed the posterior wall of the right maxillary sinus and extended to the orbital floor (Figure 2).

Because both imaging tests and histological analysis revealed a vascular tumor, we decided to proceed to a preoperative tumor embolization. Under general anesthesia, the right femoral artery was punctured, a 6 F sheath was placed and a 6 F guide catheter was advanced into the right external carotid artery. Through this, selective catheterization of branches and the internal maxillary artery (transverse facial, inferior alveolar, buccal, sphenopalatine, descending palatine) was performed. They were embolized using 300-900 μ m microparticles (Embosphere, Merit Medical). Immediate angiographic control showed the almost complete elimination of the blood supply to the tumor (Figure 3).

Tumor embolization was followed by its surgical removal. Surgery started with a partial paroti-



FIGURE 4. Partial parotidectomy on the right using intraoperative facial nerve monitoring

dectomy on the right, with a more cranially positioned incision, in order to gain better access to the zygomatic, orbital and frontal branches of the facial nerve. Using intraoperative facial nerve monitoring, the above branches were identified and protected. Afterwards, the superficial portion of the parotid gland was resected (Figure 4). The tumor was extending posteriorly up to the right temporalis muscle and the right pterygoid muscle and anteriorly/inferiorly to the alveolar process of the maxilla. The cranial insertion of both the superficial and the deep portion of the masseteric muscle and the inferior insertion of the temporalis muscle have been detached from



FIGURE 5. Re-stabilization of the middle part of the zygomatic bone with a plate



FIGURE 6. External approach via partial resection of the anterior wall of the maxillary sinus after identifying and sparing the infraorbital nerve

the zygomatic bone as the middle part of the zygomatic bone has been resected. So, the tumor was mobilized from the above region. The middle part of the zygomatic bone was re-stabilized afterwards with a plate (Figure 5). Through an endonasal endoscopic approach and 45-degree-endoscopic visualization, the medial and posterior wall of the maxillary sinus have been resected and the tumor was mobilized from the maxillary sinus and the pterygopalatine fossa, respectively. Due to extensive tumor attachments towards the oral cavity in the area of the right third molar posteriorly and inferiorly, another approach via partial resection of the anterior wall of the maxillary sinus – after identifying and sparing the infraorbital nerve – was needed to fully mobilize and resect the tumor (Figure 6). Complete excision of the tumor and satisfactory cosmetic results were achieved. The specimen was sent for histological analysis (Figure 7). The findings confirmed the diagnosis of SFT. The patient's treatment completed with radiation therapy, with good effect on locoregional recurrence, at two-years follow up. However, 2.5 years later, there was recurrence in the right temporal area, that extended intracranially and pressed the dura mater. The recurrence also extended up to




FIGURE 7. The specimen after complete excision of the tumor

the orbital floor, pressing the external rectus muscle. □

DISCUSSION

Solitary fibrous tumor is a type of mesenchymal neoplasm that previously termed and diagnosed as hemangiopericytoma, localized mesothelioma, orbital fibrous histiocytoma, giant cell angiofibroma.

Based on the 2002 World Health Organization (WHO) classification system, these tumors have intermediate biological potential (rarely metastasizing). The risk for metastasis was up to 35-45% in series with a longer follow-up, as recommended in the 2020 WHO classification (1, 6, 11, 33).

Luke Stanisic et al, who conducted the most robust and recent review of the literature about SFT of the head and neck, noticed that over 587 of SFTs were found in this area since 1991. Soft tissue tumors appear to have no predilection for gender and mainly occur in fifth and sixth decade of life (34-36).

Soft tissue tumors of the head and neck usually present as painless masses that grow up slowly, often with local compressive symptoms (33). In the head and neck, the most commonly affected areas include the oral cavity, followed by the orbit, nose and paranasal sinuses (37-41). The nasopharynx, larynx, parapharyngeal space, salivary glands and thyroid are less commonly affected areas (42-46). Patil et al described the first case of SFT of the masticator space extending to the infratemporal-temporal fossa and parapharyngeal spaces (46). In our case, SFT was arising in the right masticatory coming out the right tem-

poralis muscle. The mass had intraoral extension, eroded the posterior wall of the right maxillary sinus and extended up to the infratemporal fossa.

Regarding differential diagnosis via imaging, SFT should be concerned in cases of hypervascular tumors (33). According to Demicco's model age at presentation, tumor size and mitotic index are the strongest predictors of time to metastasis and death (1).

Concerning the genetic signatures that are implicated in the onset of STF, the discovery of fusion genes between NAB2 and STAT6 in 2013 was determinant to expand knowledge on the molecular subtypes involved in SFT (6). More specifically, the fusion gene variants, NAB2 exon 4-STAT6 exon 2/3 and NAB2 exon 5/6/7-STAT6 exon 16/17/18 are identified in meningeal STFs, but all of them could play an important role for future therapies independently of the histological origin of STFs (47). Interestingly, STFs that are derived from the salivary glands and cases that demonstrate ectopic salivary glands are very rare in the intracranial environment. Molecular studies based on sophisticated and novel techniques including next-generation sequencing (NGS)-based assay with targeted RNA fusion sequencing. In one of them, the study group reported a variety of NAB2-STAT6 fusions such as NAB2ex4-STAT6ex2, NAB2ex2-STAT6ex5, NAB2ex6-STAT6ex16, NAB2ex6-STAT6ex17, NAB2ex3-STAT6ex18 and NAB2intron6-STAT6Ex17 (48). ■

CONCLUSION

Solitary fibrous tumors of the head and neck are extremely rare. To our knowledge, this is the sec-

ond reported case of SFT arising in the masticator space and the only case with extension intra-orally and in the paranasal sinuses. Differential diagnosis is difficult and impossible without immunohistochemical evaluation. Tumor embolization and complete surgical excision are the most frequently recommended treatments. Besides therapeutic approaches, genetic analysis for detecting the specific NAB2/STAT6 fusion subtype should be made for completing the whole diagnostic procedure. ■

Conflicts of interest: none declared.

Financial support: This research did not receive any specific funding, but was performed as part of authors' employment. Name of employer: Vasilios Ragos.

Data availability: Authors have used third party data (from another individual) and therefore do not own the data.

Ethics approval and consent to participate: The present report has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans.

Authors' contributions: EG, AZ, VR, GP and ET analyzed and interpreted the patient data. VR, SD, EG and GP performed the surgical treatment. ET performed the histological examination. AZ, EG, ET and GP contributed in writing the manuscript. All authors read and approved the final manuscript.

REFERENCES

1. Demicco EG, Park MS, Araujo DM, et al. Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. *Mod Pathol* 2012;25:1298-306.
2. Demicco EG, Wagner MJ, Maki RG, et al. Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model. *Mod Pathol* 2017;30:1433-1442.
3. Yoshida A, Tsuta K, Ohno M, et al. STAT6 immunohistochemistry is helpful in the diagnosis of solitary fibrous tumors. *Am J Surg Pathol* 2014;38:552-559.
4. Salas S, Resseguier N, Blay JY, et al. Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database. *Ann Oncol* 2017;28:1979-1987.
5. Demicco EG, Wani K, Ingram D, et al. TERT promoter mutations in solitary fibrous tumour. *Histopathology* 2018;73:843-851.
6. Martin-Brito J, Mondaza-Hernandez JL, Moura DS, Hindi N. A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons. *Cancers (Basel)* 2021;13:2913.
7. Lococo F, Cusumano G, Margaritora S, et al. Tapias score for predicting recurrences in resected solitary fibrous tumor of the pleura: controversial points and future perspectives emerging from an external

- validation.
Chest 2015;147:e115-e116.
8. **Fritch K, Jensch K, Moskalev EA, et al.** The impact of histopathology and NAB2-STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma. *Acta Neuropathol* 2019;137:307-319.
 9. **Gholami S, Cassidy MR, Kirane A, et al.** Size and Location are the Most Important Risk Factors for Malignant Behavior in Resected Solitary Fibrous Tumors. *Ann Surg Oncol* 2017;24:3865-3871.
 10. **Huang SC, Huang HY.** Solitary fibrous tumor: An evolving and unifying entity with unsettled issues. *Histol Histopathol* 2019;34:313-334.
 11. **Smith SC, Gooding WE, Elkins M, et al.** Solitary Fibrous Tumors of the Head and Neck: A Multi-Institutional Clinicopathologic Study. *Am J Surg Pathol* 2017;41:1642-1656.
 12. **Machado I, Nieto Morales MG, Cruz J, et al.** Solitary Fibrous Tumor: Integration of Clinical, Morphologic, Immunohistochemical and Molecular Findings in Risk Stratification and Classification May Better Predict Patient outcome. *Int J Mol Sci* 2021;22:9423.
 13. **Lu C, Alex D, Benayed R, et al.** Solitary fibrous tumor with neuroendocrine and squamous dedifferentiation: a potential diagnostic pitfall. *Hum Pathol* 2018;77:175-180.
 14. **Huang SC, Li CF, Kao YC, et al.** The clinicopathological significance of NAB2-STAT6 gene fusions in 52 cases of intrathoracic solitary fibrous tumors. *Cancer Med* 2016;5:159-168.
 15. **Tariq MU, Din NU, Abdul-Ghaffar J, Park YK.** The many faces of solitary fibrous tumor; diversity of histological features, differential diagnosis and role of molecular studies and surrogate markers in avoiding misdiagnosis and predicting the behavior. *Diagn Pathol* 2021;16:32.
 16. **Machado I, Morales GN, Cruz J, et al.** Solitary fibrous tumor: a case series identifying pathological adverse factors-implications for risk stratification and classification. *Virchows Arch* 2020;476:597-607.
 17. **Sung KS, Moon JH, Kim EH, et al.** Solitary fibrous tumor/hemangiopericytoma: treatment results based on the 2016 WHO classification. *J Neurosurg* 2018;130:418-425.
 18. **Klemperer P, Coleman BR.** Primary neoplasms of the pleura. A report of five cases. *Am J Ind Med* 1992;22:1-31.
 19. **Kleihues P, Louis DN, Scheithauer BW, et al.** The WHO classification of tumors of the nervous system. *J Neuropathol Exp Neurol* 2002;61:215-225; discussion 26-9.
 20. **Kao YC, Lin PC, Yen SL, et al.** Clinicopathological and genetic heterogeneity of the head and neck solitary fibrous tumours: a comparative histological, immunohistochemical and molecular study of 36 cases. *Histopathology* 2016;68:492-501.
 21. **Hasegawa T, Matsuno Y, Shimoda T, et al.** Extrathoracic solitary fibrous tumors: their histological variability and potentially aggressive behavior. *Hum Pathol* 1999;30:1464-1473.
 22. **Morimitsu Y, Nakajima M, Hisaoka M, Hashimoto H.** Extrapleural solitary fibrous tumor: clinicopathologic study of 17 cases and molecular analysis of the p53 pathway. *APMIS* 2000;108:617-625.
 23. **Bernardini FP, de Conciliis C, Schneider S, et al.** Solitary fibrous tumor of the orbit: is it rare? Report of a case series and review of the literature. *Ophthalmology* 2003;110:1442-1448.
 24. **Satomi T, Hasegawa O, Abukawa H, et al.** Exceptionally large solitary fibrous tumor arising from the cheek: an immunohistochemical and ultrastructural study with a review of the literature. *Med Mol Morphol* 2014;47:108-116.
 25. **Kuo WP, Sirois DA, Pemble CW.** Locally aggressive solitary fibrous tumor in the infraorbital region: a case report and review of the literature. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2001;92:308-311.
 26. **Profyris C, Soilleux E, Corkill R, Birch J.** Solitary fibrous tumour of the face: a rare case report. *J Plast Reconstr Aesthet Surg* 2010;63:e13-e15.
 27. **Yoon CM, Cho JM, Lim KR, et al.** Solitary Fibrous Tumor in Buccal Cheek Mucosa. *Arch Craniofac Surg* 2017;18(3):218-221.
 28. **Cox DP, Daniels T, Jordan RC.** Solitary fibrous tumor of the head and neck. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2010;110:79-84.
 29. **Ito H, Fukuda M, Imamura Y, Fuse H.** A malignant solitary fibrous tumor in the retroperitoneum. *Int J Clin Oncol* 2008;13:173-175.
 30. **Singh N, Collingwood R, Eich ML, et al.** NAB2-STAT6 Gene Fusions to Evaluate Primary/Metastasis of Hemangiopericytoma/Solitary Fibrous Tumors. *Am J Clin Pathol* 2021;156:906-912.
 31. **Haller F, Schlieben LD, Ferrazzi F, et al.** Lipomatous Solitary Fibrous Tumors Harbor Rare NAB2-STAT6 Fusion Variants and Show Up-Regulation of the Gene PPARC, Encoding for a Regulator of Adipocyte Differentiation. *Am J Pathol* 2021;191:1314-1324.
 32. **Bieg M, Moskalev EA, Will R, et al.** Gene Expression in Solitary Fibrous Tumors (SFTs) Correlates with Anatomic Localization and NAB2-STAT6 Gene Fusion Variants. *Am J Pathol* 2021;191:602-617.
 33. **Kunzel J, Hainz M, Ziebart T, et al.** Head and neck solitary fibrous tumors: a rare and challenging entity. *Eur Arch Otorhinolaryngol* 2016;273:1589-1598.
 34. **Stanisce L, Ahmad N, Levin K, Deckard N, Enriquez M, Brody J, et al.** Solitary Fibrous Tumors in the Head and Neck: Comprehensive Review and Analysis. *Head Neck Pathol* 2020;14:516-524.
 35. **Gold JS, Antonescu CR, Hajdu C, et al.** Clinicopathologic correlates of solitary fibrous tumors. *Cancer* 2002;94:1057-1068.
 36. **Cardillo G, Facciolo F, Cavazzana AO, et al.** Localized (solitary) fibrous tumors of the pleura: an analysis of 55 patients. *Ann Thorac Surg* 2000;70:1808-1812.
 37. **Alawi F, Stratton D, Freedman PD.** Solitary fibrous tumor of the oral soft tissues: a clinicopathologic and immunohistochemical study of 16 cases. *Am J Surg Pathol* 2001;25:900-910.
 38. **Dorfman DM, To K, Dickersin GR, et al.** Solitary fibrous tumor of the orbit. *Am J Surg Pathol* 1994;18:281-287.
 39. **Zukerberg LR, Rosenberg AE, Randolph G, et al.** Solitary fibrous tumor of the nasal cavity and paranasal sinuses. *Am J Surg Pathol* 1991;15:126-130.
 40. **Kohmura T, Nakashima T, Hasegawa Y, Matsuura H.** Solitary fibrous tumor of the paranasal sinuses. *Eur Arch Otorhinolaryngol* 1999;256:233-236.
 41. **Pasquini E, Cantaroni C, Salfi N, et al.** Endoscopic treatment of an ethmoidal solitary fibrous tumour. *J Laryngol Otol* 2003;117:889-891.
 42. **Jeong AK, Lee HK, Kim SY, Cho KJ.** Solitary fibrous tumor of the parapharyngeal space: MR imaging findings. *AJNR Am J Neuroradiol* 2002;23:473-475.
 43. **Benlyazid A, Lescanne E, Lefrancq T, et al.** Solitary fibrous tumour of the larynx: report of a case. *J Laryngol Otol* 1998;112:286-289.
 44. **Ferreiro JA, Nascimento AG.** Solitary fibrous tumour of the major salivary glands. *Histopathology* 1996;28:261-264.
 45. **Kie JH, Kim JY, Park YN, et al.** Solitary fibrous tumour of the thyroid. *Histopathology* 1997;30:365-368.
 46. **Patil VS, Vidya K, Paul SA, Tirkey AJ.** Solitary fibrous tumor of the masticator space - Report of a rare case. *Natl J Maxillofac Surg* 2022;13(Suppl 1):S159-S161.
 47. **Shirakura T, Yamada Y, Nakata S, et al.** Analysis of clinicopathological features and NAB2-STAT6 fusion variants of meningeal solitary fibrous tumor with ectopic salivary gland components in the cerebellopontine angle. *Virchows Arch* 2022;481:913-923.
 48. **Guseva NV, Tanas MR, Stence AA, et al.** The NAB2-STAT6 gene fusion in solitary fibrous tumor can be reliably detected by anchored multiplexed PCR for targeted next-generation sequencing. *Cancer Genet* 2016;209:303-312.